Importantly, prostate cancer cells are capable of metabolizing the testosterone found in FBS into dihydrotestosterone (DHT) at concentrations similar to those found in CRPC tumors (~1–10 nM) that promote AR function and CRPC growth [20, 21]. This evidence concerns the gene AR and prostate carcinoma.